Conceptual Entity

Sarepta Shifts Focus to siRNA Platform, Lays Off 500 After Elevidys Receives Black Box Warning

1 week ago talkbio0Tagged acute liver injury, black box, Cautionary Warning, ELEVIDYS, gene therapy, layoffs, Muscular Dystrophy, Duchenne, pipeline shift, restructuring, RNA, Small Interfering

Sarepta Therapeutics; siRNA platform; Elevidys; Duchenne muscular dystrophy; layoffs; black box warning; pipeline shift; acute liver injury; gene therapy; restructuring

Best Practice Customer-Facing Organization Study Report (2025) – Key Findings and Trends

1 month ago talkbio0Tagged Aortic Valve Insufficiency, Customer, customer-facing organization, Cytology diagnosis, digital transformation, DNA Integration, Optimization, Practice Experience, Report (document), self-service

customer-facing organization; best practices; 2025 report; customer experience; self-service; AI integration; CX optimization; digital transformation

23andMe to Restart Auction After Former CEO Anne Wojcicki Outbids Regeneron

2 months ago talkbio0Tagged Anne Wojcicki, asset, auction, Bankruptcy, Regeneron, Sales - occupational activity, Science of genetics, TTAM

23andMe; auction; Anne Wojcicki; Regeneron; TTAM Research Institute; bankruptcy; asset sale; genetics

iTeos to Shut Down Operations After TIGIT Therapy Setback

2 months ago talkbio0Tagged asset, belrestotug, Clinical trial failure, ENT1, EOS-215, EOS-984, Exit, Failure (biologic function), immuno-oncology, iTeos, Obesity, Programs - Publication Format, Sales - occupational activity, SmithKline Beecham, TIGIT gene

iTeos Therapeutics; TIGIT failure; GSK exit; clinical trial failure; belrestotug; asset sale; immuno-oncology; EOS-984; EOS-215; ENT1 obesity program

Applied Therapeutics’ Rare Disease Drug Fails Another Phase 3 Trial After FDA Rejection

2 months ago talkbio0Tagged Aldose Reductase Inhibitor, Apply, Cautionary Warning, Classical galactosemia, clinical trial conduct, Govorestat, Infrequent, Rejection, United States Food and Drug Administration

Applied Therapeutics; govorestat; rare disease; phase 3 failure; FDA rejection; classic galactosemia; aldose reductase inhibitor; clinical trial conduct; FDA warning letter

Roche injects $550M into Indianapolis hub to scale up CGM production

2 months ago talkbio0Tagged Continuous glucose monitoring, Indianapolis, Investments, Manufacture, production, Roche (company), United States

Indianapolis, Roche (company), Continuous glucose monitoring, production, Manufacture, Investments, United States

Protect Your Trial Data: Endpoint, Imaging, and Safety Review

3 months ago talkbio0Tagged Biomechanical compliance, Clinical Trials, CTMS, Diagnostic Imaging, Encryption, End Point, General Data Protection Regulation, safety review, Security - service

Clinical Trials, Diagnostic Imaging, Security – service, End Point, safety review, General Data Protection Regulation, Biomechanical compliance, CTMS, Encryption

Ex-FDA leader joins new initiative designed to fight ‘unfortunate reality’ of vaccine landscape

3 months ago talkbio0Tagged Ex-FDA, Initiative, Intact, M.D., Misinformation, Policy, Project, reality, Recommendation, threat, Vaccines

Vaccines, Project, Misinformation, Initiative, Policy, Intact, Ex-FDA, threat, Recommendation, M.D., reality

Bristol Myers’ schizophrenia drug Cobenfy stumbles as adjunctive treatment, denting blockbuster plan

3 months ago talkbio0Tagged Adjunctive Orthodontic Procedure, Antipsychotic Agents, Cobenfy, Improvement, Myers, Schizophrenia, Single Agent Therapy, Statistical Significance

Cobenfy, Schizophrenia, Antipsychotic Agents, Adjunctive Orthodontic Procedure, Myers, Statistical Significance, Improvement, Single Agent Therapy

DualityBio Pursues $200M IPO in Hong Kong Amid Volatile Market Conditions

4 months ago talkbio0Tagged Antibody-Drug, BioNTech, biotech sector, DualityBio, global trade tensions, Hong, Immunostimulating conjugate (antigen), Investments, IPO, Kong, Market, Stock exchange, upheaval

DualityBio, IPO, Hong Kong Stock Exchange, biotech investment, antibody-drug conjugates, BioNTech, market upheaval, global trade tensions, biotech sector growth.